Exploring the Interplay Between Chronic Kidney Disease and Cardiovascular Disease

Author(s):

Anuradha Lala-Trindade, MD,Edgar Lerma, MD

Key Takeaways

Pharmacotherapeutic advancements, including SGLT2 inhibitors and finerenone, have transformed CKD management in type 2 diabetes, offering new treatment options.
Finerenone has demonstrated efficacy in reducing CKD progression and cardiovascular risks, supported by FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF trial data.
Collaboration between cardiologists and nephrologists is essential for managing CKD and cardiovascular disease, emphasizing dual-benefit therapies.
An integrated approach to CKD and cardiovascular disease management aims to improve patient outcomes by addressing both conditions simultaneously.

In this first of this 5-part series, Lerma and Lala-Trindade discuss the interplay between chronic kidney disease and cardiovascular disease.

Now Viewing

EP: 1.Exploring the Interplay Between Chronic Kidney Disease and Cardiovascular Disease

EP: 2.Understanding the Effects of nsMRA vs MRA

EP: 3.Addressing Cardiovascular Risk in CKD Patients

EP: 4.Applying Recent Guidelines, 4-Pillared Approach to CKD Care

EP: 5.Exploring the Cardiovascular Benefits, Potential of Finerenone

Management of chronic kidney disease among patients with type 2 diabetes has undergone significant change in the last decade. Once handcuffed by a lack of safe and efficacious options, changing standards of care coming as the result of pharmacotherapeutic advancement have ushered in a new era of management for this patient population.

This change has been spearheaded by 2 particular classes—a familiar face in the form of SGLT2 inhibitors and the novel nonsteroidal mineralocorticoid receptor antagonist (nsMRA) finerenone (Kerendia), which received approval in July 2021 for reducing the risk of sustained eGFR decline, kidney failure, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease associated with type 2 diabetes.

Finerenone first captivated the attention of nephrologists, endocrinologists, and other providers managing patients with type 2 diabetes with the release of data from the FIDELIO-DKD and FIGARO-DKD trials. The number of specialists captivated by the agent and its potential benefit grew with the release of data surrounding the cardiovascular benefits among patients with heart failure observed within the FINEARTS-HF trial at the European Society of Cardiology Congress 2024.

In this segment, which is part X of a 5-part series, discussants Edgar Lerma, MD, a nephrologist, and Anuradha Lala-Trindade, MD, a cardiologist, explore the critical relationship between chronic kidney disease and cardiovascular disease, emphasizing the impact of chronic kidney disease on cardiovascular risk and treatment decisions. Lerma highlights the long-recognized connection between heart and kidney health, noting that chronic kidney disease patients, especially those with end-stage disease, face heightened cardiovascular risks, often experiencing complications like heart failure, arrhythmias, and coronary artery disease. He also underscores that a significant proportion of chronic kidney disease cases stem from diabetes and hypertension, conditions that intertwine chronic kidney disease and cardiovascular outcomes.

The conversation then pivots to the importance of collaboration between cardiologists and nephrologists in managing these complex cases. Lerma emphasizes that therapies aimed at slowing chronic kidney disease progression can concurrently reduce cardiovascular complications, thus underscoring a dual benefit approach. As the dialogue unfolds, Lala-Trindade and Lerma discuss the transformative potential of recent clinical trials, with a special focus on finerenone, a promising therapy targeting both chronic kidney disease progression and cardiovascular risk. This collaborative perspective aims to provide a more integrated, effective approach to care for patients navigating both chronic kidney disease and cardiovascular disease.

Discussants Background:

Edgar Lerma, MD, a clinical professor of Medicine in the Section of Nephrology at the University of Illinois at Chicago and a nephrologist with Associates In Nephrology based in Chicago.

Anuradha Lala-Trindade, MD, the director of Heart Failure Research, program director of the Advanced Heart Failure and Transplant Fellowship, and associate professor of Medicine at The Mount Sinai Fuster Heart Hospital & Department of Population Health Science and Policy.

Relevant disclosures for Lerma include Akebia, Astra Zeneca, Bayer, Boehringer Ingelheim, Glaxo Smith Kline, Otsuka, Travere, Vifor, and Fresenius. Relevant disclosures for Lala-Trindade include Merck, AstraZeneca, Cytokinetics, and Novartis.

References:

Campbell P. Finerenone (Kerendia) approved for chronic kidney disease associated with type 2 diabetes. HCP Live. July 9, 2021. Accessed October 23, 2024. https://www.hcplive.com/view/finerenone-kerendia-approved-chronic-kidney-disease-associated-with-type-2-diabetes.
Campbell P. FDA updates Finerenone label to reflect Cardiovascular Outcomes Data. HCP Live. September 8, 2022. Accessed October 23, 2024. https://www.hcplive.com/view/fda-updates-finerenone-label-to-reflect-cardiovascular-outcomes-data.
Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. Published online September 1, 2024. doi:10.1056/NEJMoa2407107